AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19538811 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (2250 mg K)
Number of subjects: 12
Study 19538811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17091418 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 46
Study 17091418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine treatment
Number of subjects: 46
Study 15037402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (80 mg daily)
Number of subjects: 60
Study 15037402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11894976 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (0.45 g ethanol/kg)
Number of subjects: 14
Study 11894976 — intervention group
Group type: COMPARATOR
Intervention: Water ingestion
Number of subjects: 14
Study 9592984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose, continuous intravenous infusion)
Number of subjects: 70
Study 11654164 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with AIDS (PWAs)
Number of subjects: 600
Study 11654164 — intervention group
Group type: COMPARATOR
Intervention: Persons with homicidal intent
Number of subjects: 600
Study 3203010 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly maintenance therapy consisting of thioguanine 100 mg/m2 twice daily and etoposide 100 mg/m2 twice daily (days 1-5) alternating with CCNU 50 mg/m2 once to a total of 6 courses.
Number of subjects: 64
Study 3203010 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 64
Study 30477620 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV subtype A
Number of subjects: 200
Study 30477620 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV subtype B
Number of subjects: 200
Study 30477620 — intervention group
Group type: EXPERIMENTAL
Intervention: NA1 genotype
Number of subjects: 200
Study 30477620 — intervention group
Group type: EXPERIMENTAL
Intervention: ON1 genotype
Number of subjects: 200
Study 30477620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide and amino acid homology
Number of subjects: 200
Study 30477620 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolates of subtype A
Number of subjects: 200
Study 28463149 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month plus an additional 24 months of monthly goserelin)
Number of subjects: 1554
Study 28463149 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD)
Number of subjects: 1554
Study 28463149 — intervention group
Group type: COMPARATOR
Intervention: Short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month)
Number of subjects: 1554
Study 23771813 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (intervention group)
Number of subjects: 292
Study 23771813 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (control group)
Number of subjects: 292
Study 23540577 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy program
Number of subjects: 452
Study 21958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control targeting HbA(1c) to less than 6.0% (42 mmol/mol)
Number of subjects: 2977
Study 21958949 — intervention group
Group type: COMPARATOR
Intervention: Standard glycaemic control targeting HbA(1c) to 7.0-7.9% (53-63 mmol/mol)
Number of subjects: 2977
Study 21958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 2977
Study 21958949 — intervention group
Group type: COMPARATOR
Intervention: Standard glycaemic control
Number of subjects: 2977
Study 18241743 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR with Zenith TX2 Endovascular Graft
Number of subjects: 230
Study 18241743 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 230
Study 16646115 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic brain injury (TBI) group
Number of subjects: 11
Study 16646115 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age, sex, and education), N=13
Number of subjects: 11
Study 16646115 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 11
Study 12707558 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 156
Study 12707558 — intervention group
Group type: COMPARATOR
Intervention: Inpatient psychiatric hospitalization
Number of subjects: 156
Study 10897077 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of family relations and mothers' perceptions of daughters' weight at Time 1
Number of subjects: 77
Study 10897077 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous body image and dieting behaviors
Number of subjects: 77
Study 10897077 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls' body image
Number of subjects: 77
Study 8797346 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (E7155) low dose (0.025 mmol/kg)
Number of subjects: 79
Study 8797346 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (E7155) medium dose (0.05 mmol/kg)
Number of subjects: 79
Study 8797346 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (E7155) high dose (0.1 mmol/kg)
Number of subjects: 79
Study 1514709 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol, 150 mg iodine/mL
Number of subjects: 100
Study 1514709 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol, 150 mg iodine/mL
Number of subjects: 100
Study 6402934 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP regimen (doxorubicin and cisplatin plus hexamethylmelamine and cyclophosphamide)
Number of subjects: 100
Study 6402934 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin-cisplatin (AP) regimen
Number of subjects: 100
Study 31968102 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HDL-C levels (genetic predisposition)
Number of subjects: 617303
Study 31968102 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C raising genetic variants in the gene locus of CETP inhibitors
Number of subjects: 617303
Study 31582195 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 26
Study 31582195 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy for Cognitively Impaired
Number of subjects: 26
Study 30002437 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05280014
Number of subjects: 226
Study 30002437 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab-EU
Number of subjects: 226
Study 26963909 — intervention group
Group type: EXPERIMENTAL
Intervention: OEPA chemotherapy
Number of subjects: 100
Study 24504431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI) for four times per week for 15 min at 15°C
Number of subjects: 34
Study 24504431 — intervention group
Group type: COMPARATOR
Intervention: Control (passive recovery)
Number of subjects: 34
Study 22540738 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced handling and positioning experiences
Number of subjects: 28
Study 22540738 — intervention group
Group type: COMPARATOR
Intervention: Control experiences
Number of subjects: 28
Study 20075695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplementation for fecal incontinence (FI), specific dosage and duration not mentioned.
Number of subjects: 0
Study 17327409 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (5, 10, 25, 30, 50, and 75 mg)
Number of subjects: 73
Study 17327409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16263675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (North American Rescue Products, Inc.)
Number of subjects: 30
Study 16263675 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency & Military Tourniquet (Delfi Medical Innovations, Inc.)
Number of subjects: 30
Study 16263675 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Operations Forces Tactical Tourniquet (Tactical Medical Solutions, LLC)
Number of subjects: 30
Study 16263675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth tourniquet tested in experiment I
Number of subjects: 30
Study 16263675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth tourniquet tested in experiment II
Number of subjects: 30
Study 16968792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose PET scan in hyperthyroid patients
Number of subjects: 12
Study 16968792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose PET scan in hyperthyroid patients with increased anxiety
Number of subjects: 12
Study 10642736 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized short echo time magnetic resonance (MR) spectra analysis in active lesions
Number of subjects: 0
Study 10642736 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized short echo time magnetic resonance (MR) spectra analysis in chronic lesions
Number of subjects: 0
Study 10642736 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized short echo time magnetic resonance (MR) spectra analysis in normal‐appearing white matter
Number of subjects: 0
Study 8672759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg daily for 3 weeks, 15 mg for 1 week, and no prednisolone for 2 weeks prior to lymphoblastoid IFN therapy (Group 1)
Number of subjects: 100
Study 8672759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily for 2 weeks, 30 mg for 2 weeks, 20 mg for 2 weeks, and no prednisolone for 2 weeks prior to INF alpha‐2a therapy (Group 2)
Number of subjects: 100
Study 8672759 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of prednisolone (40 mg)
Number of subjects: 100
Study 8672759 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cirrhotic patients
Number of subjects: 100
Study 8672759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with clinical rebound
Number of subjects: 100
Study 1298321 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrix System rubber points alone
Number of subjects: 30
Study 1298321 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrix System rubber points plus Caulk's Prisma Gloss fine and super-fine pastes
Number of subjects: 30
Study 1298321 — intervention group
Group type: EXPERIMENTAL
Intervention: Caulk's Enhance disks plus Caulk's Prisma Gloss fine and super-fine pastes
Number of subjects: 30
Study 1298321 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Sof-flex disks alone
Number of subjects: 30
Study 1298321 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhance disks only without using the Prisma Gloss pastes
Number of subjects: 30
Study 1298321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof-flex disks plus Kerr's Lustre Paste
Number of subjects: 30
Study 1298321 — intervention group
Group type: COMPARATOR
Intervention: Sof-flex disks
Number of subjects: 30
Study 6402387 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol (EE) administered orally at 36 hours after LH peak and again at 48 hours
Number of subjects: 12
Study 6402387 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsies from treatment cycle
Number of subjects: 12
Study 6402387 — intervention group
Group type: COMPARATOR
Intervention: Endometrial biopsies from control cycle
Number of subjects: 12
Study 31774400 — intervention group
Group type: EXPERIMENTAL
Intervention: MPathic-VR simulation
Number of subjects: 206
Study 31774400 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 29076878 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing voucher receipt (intervention)
Number of subjects: 0
Study 26773183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy (QT) for 10 days
Number of subjects: 390
Study 26773183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST) for 10 days
Number of subjects: 390
Study 26773183 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT) for 10 days
Number of subjects: 390
Study 24707778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive inhibitory control training
Number of subjects: 122
Study 24707778 — intervention group
Group type: COMPARATOR
Intervention: Active control (nonadaptive version)
Number of subjects: 122
Study 22189188 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP joint blocking splint
Number of subjects: 30
Study 22189188 — intervention group
Group type: COMPARATOR
Intervention: DIP joint blocking splint
Number of subjects: 30
Study 20457580 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygoma anchorage system (ZAS) with PG retraction springs
Number of subjects: 30
Study 20457580 — intervention group
Group type: COMPARATOR
Intervention: PG retraction springs only
Number of subjects: 30
Study 18614781 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (367 patients)
Number of subjects: 1069
Study 18614781 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (CPAP, 346 patients)
Number of subjects: 1069
Study 18614781 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIPPV, 356 patients)
Number of subjects: 1069
Study 18614781 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (CPAP)
Number of subjects: 1069
Study 15642905 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scans before antiepileptic medication and follow-up MRI scans after 1, 2 to 3, and 5 years of treatment
Number of subjects: 103
Study 15642905 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual analysis of patients with HC damage
Number of subjects: 103
Study 15642905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HC damage
Number of subjects: 103
Study 12145071 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm IVRA with 100 mg lidocaine and 10 mg ketorolac
Number of subjects: 100
Study 12145071 — intervention group
Group type: COMPARATOR
Intervention: Upper Arm IVRA with 200 mg lidocaine and 20 mg ketorolac
Number of subjects: 100
Study 10523683 — intervention group
Group type: EXPERIMENTAL
Intervention: High dThdPase activity in primary tumors
Number of subjects: 0
Study 10523683 — intervention group
Group type: EXPERIMENTAL
Intervention: High dThdPase activity in tumors with venous invasion
Number of subjects: 0
Study 10523683 — intervention group
Group type: EXPERIMENTAL
Intervention: High dThdPase activity in metastatic lymph nodes
Number of subjects: 0
Study 10523683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral heterogeneity of dThdPase activity
Number of subjects: 0
Study 7733838 — intervention group
Group type: EXPERIMENTAL
Intervention: Levorotatory form of hydroxytryptophan (1000 mg/d)
Number of subjects: 39
Study 7733838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31779988 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy + TENS
Number of subjects: 88
Study 31779988 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Number of subjects: 88
Study 31779988 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 88
Study 31779988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 29382250 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Enabling and Support (IES)
Number of subjects: 61
Study 29382250 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 61
Study 26585355 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 170
Study 26585355 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 170
Study 24402803 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancement of catheters with a leading guidewire over the aortic arch
Number of subjects: 41
Study 24402803 — intervention group
Group type: COMPARATOR
Intervention: Advancement of catheters without a guidewire over the aortic arch
Number of subjects: 41
Study 22495787 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 vaginal gel
Number of subjects: 60
Study 22495787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19369187 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (n = 56)
Number of subjects: 107
Study 19369187 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control group, n = 46)
Number of subjects: 107
Study 17962710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 141
Study 17962710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 15024596 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Stapled Trans‐Anal Prolapsectomy with Perineal Levatorplasty (STAPL Group)
Number of subjects: 50
Study 15024596 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Stapled Trans‐Anal Rectal Resection (STARR Group)
Number of subjects: 50
Study 15024596 — intervention group
Group type: COMPARATOR
Intervention: STARR Group
Number of subjects: 50
Study 15024596 — intervention group
Group type: COMPARATOR
Intervention: STAPL Group
Number of subjects: 50
Study 11597813 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Hyperfractionated (AH) whole‐brain radiation therapy (1.6 Gy b.i.d. to 54.4 Gy)
Number of subjects: 445
Study 11597813 — intervention group
Group type: COMPARATOR
Intervention: Accelerated Fractionation (AF) whole‐brain radiation therapy (3 Gy q.d. to 30 Gy)
Number of subjects: 445
Study 11597813 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of brain metastases (radiologically controlled)
Number of subjects: 445
Study 11597813 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled brain metastases
Number of subjects: 445
Study 9688452 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 3 g daily + amikacin (reference regimen)
Number of subjects: 608
Study 9688452 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam + amikacin
Number of subjects: 608
Study 8082347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus rt-PA (0.6 mg/kg/15 min, maximum of 50 mg)
Number of subjects: 90
Study 8082347 — intervention group
Group type: COMPARATOR
Intervention: 2-h rt-PA (100 mg over 2 h)
Number of subjects: 90
Study 8082347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus rt-PA
Number of subjects: 90
Study 8082347 — intervention group
Group type: COMPARATOR
Intervention: 2-h rt-PA
Number of subjects: 90
Study 2537125 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular non-absorbable suture for 6 months
Number of subjects: 0
Study 2537125 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular polyglycolic acid
Number of subjects: 0
Study 2537125 — intervention group
Group type: COMPARATOR
Intervention: Conventional interrupted sutures
Number of subjects: 0
Study 1091965 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid (ASA) preparation
Number of subjects: 18
Study 1091965 — intervention group
Group type: COMPARATOR
Intervention: Plain acetylsalicylic acid (ASA) tablets
Number of subjects: 18
Study 31532029 — intervention group
Group type: EXPERIMENTAL
Intervention: subanesthetic S-Ketamine
Number of subjects: 24
Study 31532029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30159738 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovisc™ (4 ml single injection)
Number of subjects: 369
Study 30159738 — intervention group
Group type: COMPARATOR
Intervention: Saline (4 ml injection of 0.9% saline)
Number of subjects: 369
Study 28287802 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy® Plus group prenatal care
Number of subjects: 1135
Study 28287802 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 1135
Study 28287802 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms from second to third trimester
Number of subjects: 1135
Study 28287802 — intervention group
Group type: EXPERIMENTAL
Intervention: Third trimester depressive symptoms
Number of subjects: 1135
Study 25269659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump 2 (Asante Snap Insulin Pump)
Number of subjects: 28
Study 25269659 — intervention group
Group type: COMPARATOR
Intervention: Pump 1 (Medtronic Revel 723)
Number of subjects: 28
Study 22834767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily for 6 weeks
Number of subjects: 60
Study 22834767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21270359 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg/d cholecalciferol (D3) supplementation
Number of subjects: 413
Study 21270359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 21270359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg/d cholecalciferol (D3)
Number of subjects: 413
Study 21270359 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg/d cholecalciferol (D3)
Number of subjects: 413
Study 19292217 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ROM prosthesis
Number of subjects: 10
Study 17137511 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous adenosine
Number of subjects: 12
Study 17137511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12672714 — intervention group
Group type: COMPARATOR
Intervention: Baseline (BL) diet (35% fat, 14% SFA, 13% MUFA, 8% PUFA, 147 mg cholesterol/1000 kcal)
Number of subjects: 10
Study 12672714 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat (RF) diet (26% fat, 4% SFA, 11% MUFA, 11% PUFA, 45 mg cholesterol/1000 kcal)
Number of subjects: 10
Study 12672714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet (15% fat, 5% SFA, 5% MUFA, 3% PUFA, 35 mg cholesterol/1000 kcal)
Number of subjects: 10
Study 12672714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat calorie reduced (LFCR) diet
Number of subjects: 10
Study 10929448 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional needle placement and manipulation
Number of subjects: 67
Study 10929448 — intervention group
Group type: COMPARATOR
Intervention: Needles placed away from classic positions and not manipulated (Control)
Number of subjects: 67
Study 8827134 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decision rules with feedback at 22 degrees C
Number of subjects: 22
Study 8827134 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decision rules with feedback at 40 degrees C
Number of subjects: 22